TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH PRAVASTATIN (CS-514) AND OR CHOLESTYRAMINE - (THE SPANISH MULTICENTER PRAVASTATIN STUDY)

被引：0
|
作者：
CARMENA, R
DEOYA, M
FRANCO, M
MARTINEZ, M
MATA, P
GOMEZ, J
SERRANO, S
ALVAREZSALA, L
MATESANZ, J
RUBIO, M
GRAS, X
机构：
来源：
ATHEROSCLEROSIS VIII | 1989年 / 817卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：757 / 760
页数：4
相关论文
共 50 条
  • [31] LOVASTATIN (MEVINOLIN) IN THE TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - A MULTICENTER STUDY
    HAVEL, RJ
    HUNNINGHAKE, DB
    ILLINGWORTH, DR
    LEES, RS
    STEIN, EA
    TOBERT, JA
    BACON, SR
    BOLOGNESE, JA
    FROST, PH
    LAMKIN, GE
    LEES, AM
    LEON, AS
    GARDNER, K
    JOHNSON, G
    MELLIES, MJ
    RHYMER, PA
    TUN, P
    ANNALS OF INTERNAL MEDICINE, 1987, 107 (05) : 609 - 615
  • [32] Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia:: A prospective clinical follow-up study
    Hedman, M
    Matikainen, T
    Föhr, A
    Lappi, M
    Piippo, S
    Nuutinen, M
    Antikainen, M
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04): : 1942 - 1952
  • [33] PRAVASTATIN, CHOLESTYRAMINE AND GEMFIBROCIL IN THE LONG-TERM TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA - AN OPEN, RANDOMIZED, PARALLEL COMPARISON
    DITSCHUNEIT, HH
    DREYER, M
    DAMMANN, HG
    DITSCHUNEIT, H
    MEDIZINISCHE KLINIK, 1991, 86 (03) : 142 - 148
  • [34] DOSE-DEPENDENT HYPOLIPIDEMIC EFFECT OF AN INHIBITOR OF HMG-COA REDUCTASE, PRAVASTATIN (CS-514), IN HYPERCHOLESTEROLEMIC SUBJECTS - A DOUBLE BLIND TEST
    SAITO, Y
    GOTO, Y
    NAKAYA, N
    HATA, Y
    HOMMA, Y
    NAITO, C
    HAYASHI, H
    ITO, H
    YAMAMOTO, M
    TAKEUCHI, I
    MORI, K
    HARA, T
    YOSHIDA, S
    SHIRAI, K
    SASAKI, N
    SHINOMIYA, M
    MURANO, S
    MORISAKI, N
    NISHIIDE, T
    KANZAKI, T
    WATANABE, N
    ISHIKAWA, T
    ATHEROSCLEROSIS, 1988, 72 (2-3) : 205 - 211
  • [35] INDUCTION OF HEPATIC LDL RECEPTORS IN NORMAL AND HETEROZYGOUS WHHL RABBITS TREATED WITH CS-514, AN INHIBITOR OF HMG-COA REDUCTASE, IN COMBINATION WITH CHOLESTYRAMINE
    KUME, N
    MIKAMI, A
    ISHII, K
    NAGANO, Y
    YOKODE, M
    KITA, T
    ARTERIOSCLEROSIS, 1987, 7 (05): : A548 - A549
  • [36] PLASMA-LIPOPROTEIN CHANGES AFTER TREATMENT WITH PRAVASTATIN AND GEMFIBROZIL IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    FRANCESCHINI, G
    SIRTORI, M
    VACCARINO, V
    GIANFRANCESCHI, G
    CHIESA, G
    SIRTORI, CR
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1989, 114 (03): : 250 - 259
  • [37] Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia
    Kajinami, K
    Yagi, K
    Higashikata, T
    Inazu, A
    Koizumi, J
    Mabuchi, H
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (01): : 113 - 117
  • [38] EFFECT OF PRAVASTATIN, CHOLESTYRAMINE OR THEIR COMBINATION IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN ELDERLY HYPERTENSIVE PATIENTS (VOL 9, PG 314, 1995)
    MORGAN, TO
    ANDERSON, A
    MORGAN, O
    BERTRAM, D
    PIGEON, A
    RENNIE, G
    JOUGHIN, J
    CLINICAL DRUG INVESTIGATION, 1995, 10 (01) : 63 - 63
  • [39] THE RED-LIP STUDY - PRAVASTATIN IN PRIMARY ISOLATED HYPERCHOLESTEROLEMIA - AN OPEN, PROSPECTIVE, MULTICENTER TRIAL
    SINZINGER, H
    PIRICH, C
    WIENER KLINISCHE WOCHENSCHRIFT, 1994, 106 (23) : 721 - 727
  • [40] Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin
    Ryu, Sung Kee
    Hutten, Barbara A.
    Vissers, Maud N.
    Wiegman, Albert
    Kastelein, John J. P.
    Tsimikas, Sotirios
    JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (01) : 50 - 56
12345